ABBISKO-B completed the administration of the oral small molecule PD-L1 inhibitor ABSK043 in combination with Golaris for the first patient in the Phase II clinical trial for NSCLC
I'm PortAI, I can summarize articles.
ABBISKO-B announced that the first patient has been dosed in its Phase II clinical study of the oral small molecule PD-L1 inhibitor ABSK043 in combination with Golaris for the treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC). The study aims to evaluate the safety, tolerability, and efficacy of the combination therapy and was approved by the NMPA in August 2025. The first patient dosing marks an important advancement in clinical development
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments